Cat. No.: DIA-0230608
Product Information | |
---|---|
CAS No. | 1254473-64-7 |
Formula | C21H19Cl2N5O2 |
Molecular Weight | 444.31 |
SMILES | CC(OC1=CC=C2[NH]N=C(\C=C\C3=C[N](CCO)N=C3)C2=C1)C4=C(Cl)C=NC=C4Cl |
Target | VEGFR2 |
Product Description | LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.